Biocatalysis for pharmaceutical intermediates: the future is now.
Biocatalysis is continuing to gain momentum and is now becoming a key component in the toolbox of the process chemist, with a place alongside chemocatalysis and chromatographic separations. The pharmaceutical industry demands a speed of development that must be on a parallel with conventional chemistry and high optical purity for complex compounds with multiple chiral centres. This review describes how these demands are being addressed to make biocatalysis successful, particularly by the use of micro-scale technology for high-speed catalyst screening and process development alongside discipline integration of biology and engineering with chemistry. Developments in recombinant technology will further expand the repertoire of biocatalysis in the coming years to new chemistries and enable catalyst design to fit the process. Further development of biocatalysis for green chemistry and high productivity processes can also be expected.
Pollard
David J
DJ
Process Research, Merck Research Laboratories, Merck and Co, PO Box 2000, Rahway, NJ 07065, USA.
Woodley
John M
JM
D001711:Biotransformation; D002384:Catalysis; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D004345:Drug Industry / Q000639:trends; D004800:Enzymes, Immobilized / Q000737:chemistry*; D008956:Models, Chemical; D004364:Pharmaceutical Preparations / Q000138:chemical synthesis* / Q000302:isolation & purification
D004800:Enzymes, Immobilized; D004364:Pharmaceutical Preparations